PH12012502070A1 - Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders - Google Patents

Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Info

Publication number
PH12012502070A1
PH12012502070A1 PH1/2012/502070A PH12012502070A PH12012502070A1 PH 12012502070 A1 PH12012502070 A1 PH 12012502070A1 PH 12012502070 A PH12012502070 A PH 12012502070A PH 12012502070 A1 PH12012502070 A1 PH 12012502070A1
Authority
PH
Philippines
Prior art keywords
tyrosine kinase
protein tyrosine
inhibitors
kinase activity
ophthalmic disorders
Prior art date
Application number
PH1/2012/502070A
Other languages
English (en)
Inventor
Lijie Zhan
Stephen William Claridge
Arkadii Vaisburg
Frã©Dã©Ric Gaudette
Franck Raeppel
Stã©Phane Raeppel
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of PH12012502070A1 publication Critical patent/PH12012502070A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH1/2012/502070A 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders PH12012502070A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000390 WO2011127565A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Publications (1)

Publication Number Publication Date
PH12012502070A1 true PH12012502070A1 (en) 2015-05-08

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2012/502073A PH12012502073A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity
PH1/2012/502070A PH12012502070A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PH1/2012/502073A PH12012502073A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Country Status (19)

Country Link
US (3) US8455484B2 (enExample)
EP (2) EP2563794A4 (enExample)
JP (2) JP2013525286A (enExample)
KR (2) KR20130100234A (enExample)
CN (2) CN102947315A (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241422B2 (enExample)
CA (2) CA2796054A1 (enExample)
CO (2) CO6640224A2 (enExample)
EA (2) EA201291052A1 (enExample)
MX (2) MX2012012032A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602948A (enExample)
PH (2) PH12012502073A1 (enExample)
SG (2) SG184883A1 (enExample)
TW (2) TW201204734A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008293038B2 (en) * 2007-08-29 2013-08-29 Mirati Therapeutics, Inc. Inhibitors of protein tyrosine kinase activity
EP2332536A1 (en) * 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
SG184883A1 (en) * 2010-04-16 2012-11-29 Methylgene Inc Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1957498B1 (en) * 2005-05-20 2017-02-15 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
AU2008293038B2 (en) 2007-08-29 2013-08-29 Mirati Therapeutics, Inc. Inhibitors of protein tyrosine kinase activity
EP2332536A1 (en) * 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
SG184883A1 (en) * 2010-04-16 2012-11-29 Methylgene Inc Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity

Also Published As

Publication number Publication date
CN103025740B (zh) 2015-07-01
AU2011241422B2 (en) 2015-05-07
CN102947315A (zh) 2013-02-27
SG184883A1 (en) 2012-11-29
CA2796008A1 (en) 2011-10-20
TW201204735A (en) 2012-02-01
MY157319A (en) 2016-05-31
US20110257100A1 (en) 2011-10-20
KR20130100234A (ko) 2013-09-10
CO6630193A2 (es) 2013-03-01
AR080875A1 (es) 2012-05-16
TW201204734A (en) 2012-02-01
NZ602954A (en) 2014-11-28
MX2012012031A (es) 2012-12-17
EP2563794A1 (en) 2013-03-06
US8455484B2 (en) 2013-06-04
AU2011241420B2 (en) 2015-04-16
EA201291055A1 (ru) 2013-09-30
CO6640224A2 (es) 2013-03-22
JP2013523846A (ja) 2013-06-17
ZA201207482B (en) 2013-09-25
MX2012012032A (es) 2012-12-17
SG184882A1 (en) 2012-11-29
WO2011127565A1 (en) 2011-10-20
AU2011241422A1 (en) 2012-11-01
EA201291052A1 (ru) 2013-04-30
US8906852B2 (en) 2014-12-09
JP2013525286A (ja) 2013-06-20
EP2563795A1 (en) 2013-03-06
KR20130058006A (ko) 2013-06-03
AR080871A1 (es) 2012-05-16
CN103025740A (zh) 2013-04-03
WO2011127567A1 (en) 2011-10-20
CA2796054A1 (en) 2011-10-20
EP2563794A4 (en) 2013-12-04
ZA201207557B (en) 2013-06-26
US20110257175A1 (en) 2011-10-20
PH12012502073A1 (en) 2013-02-11
NZ602948A (en) 2014-09-26
EP2563795A4 (en) 2013-10-23
UA108878C2 (ru) 2015-06-25
US20140315801A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
CA2871471C (en) Dna-pk inhibitors
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
PH12013502612A1 (en) Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2012037155A3 (en) Tyrosine kinase inhibitors
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
BR112013009260A2 (pt) compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak